{ "dc.contributor.author": "Giró Perafita, Ariadna" , "dc.contributor.author": "Sarrats Carbó, Ariadna" , "dc.contributor.author": "Perez Bueno, Ferran" , "dc.contributor.author": "Oliveras, Glòria" , "dc.contributor.author": "Buxó Pujolràs, Maria" , "dc.contributor.author": "Brunet i Vidal, Joan" , "dc.contributor.author": "Viñas, Gemma" , "dc.contributor.author": "Puig i Miquel, Teresa" , "dc.date.accessioned": "2019-12-09T12:48:19Z" , "dc.date.available": "2019-12-09T12:48:19Z" , "dc.date.issued": "2017-09-26" , "dc.identifier.issn": "1949-2553" , "dc.identifier.uri": "http://hdl.handle.net/10256/17320" , "dc.description.abstract": "Triple-Negative Breast Cancer (TNBC) has poor prognosis and no approved targeted therapy. We previously showed that the enzyme fatty acid synthase (FASN) was largely expressed in a small TNBC patients’ cohort and its inhibition synergized with cetuximab in TNBC preclinical mouse models. Here, we evaluated FASN and EGFR expression in a cohort of TNBC patients and we study their prognostic role and their association with clinico-histopathological features, intrinsic TNBC subtypes and survival. FASN, EGFR, CK5/6 and vimentin expression were retrospective evaluated by Immunohistochemistry in 100 primary TNBC tumors. FASN expression was classified into high and low FASN groups. EGFR, CK5/6 and vimentin expression were used in TNBC intrinsic subtypes classification. FASN was expressed in most of the TNBC patients but did not correlate with overall survival or disease-free survival in this cohort. High FASN group was significantly associated with positive node status. FASN expression was significantly higher in Basal-Like patients than in Mesenchymal-Like ones. EGFR expression was positive in 50% of the tumors, and those patients showed poorer DFS. Altogether, our findings provide a rationale for further investigation the prognostic role of FASN and EGFR expression in a larger cohort of TNBC patients" , "dc.description.sponsorship": "This work was supported in part by the Spanish Instituto de Salud Carlos III (ISCIII) (FIS PI11/00692; TP and PI14/00329; TP), Fundación Ramón Areces (TP), the Catalonian Government (2014SGR00868) and the University of Girona (MPCUdG2016/036 and predoctoral grant to AG-P)" , "dc.format.mimetype": "application/pdf" , "dc.language.iso": "eng" , "dc.publisher": "Impact Journals" , "dc.relation.isformatof": "Reproducció digital del document publicat a: htps://doi.org/10.18632/oncotarget.20152" , "dc.relation.ispartof": "Oncotarget, 2017, vol. 8, núm. 43, p. 74391-74405" , "dc.relation.ispartofseries": "Articles publicats (D-CM)" , "dc.rights": "Attribution 4.0 International" , "dc.rights.uri": "http://creativecommons.org/licenses/by/4.0/" , "dc.subject": "Mama -- Càncer" , "dc.subject": "Breast cancer" , "dc.title": "Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer" , "dc.type": "info:eu-repo/semantics/article" , "dc.rights.accessRights": "info:eu-repo/semantics/openAccess" , "dc.type.version": "info:eu-repo/semantics/publishedVersion" , "dc.identifier.doi": "htps://doi.org/10.18632/oncotarget.20152" , "dc.identifier.idgrec": "027894" , "dc.type.peerreviewed": "peer-reviewed" }